Q5105Inj retacrit esrd on dialysi
Published CMS Medicare Part B payment-limit context for Q5105, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$0.797
per 100 UNITS · Medicare Part B
Up 1.1%from $0.788 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$0.8096$0.6944
2024-Q4: $0.762; 2025-Q1: $0.747; 2025-Q2: $0.707; 2025-Q3: $0.757; 2025-Q4: $0.785; 2026-Q1: $0.757; 2026-Q2: $0.788; 2026-Q3: $0.797
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Epoetin ingredient family (FDA data as of August 20, 2026).
Retacrit
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Epoetin presentations
3 other CMS codesSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J0885 | Epoetin alfa, non-esrd | $6.876 per 1000 UNITS | $7.305 per 1000 UNITS | Down 5.9% | ||
| Q4081 | Epoetin alfa, 100 units esrd | $0.688 per 100 UNITS | $0.73 per 100 UNITS | Down 5.8% | ||
| Q5106 | Inj retacrit non-esrd use | $7.968 per 1000 UNITS | $7.883 per 1000 UNITS | Up 1.1% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.